Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amfenac SCHEMBL30777846 | 1.00 | ABCB11 (0.78) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL42390 | 0.98 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL11168965 | 0.98 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL11726346 | 0.98 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9747734 | 0.98 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9747027 | 0.98 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9998546 | 0.98 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL11467022 | 0.97 | ABCB11 (0.74) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL10824627 | 0.97 | ABCB11 (0.74) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL10589034 | 0.97 | ABCB11 (0.74) | ABCB11LMNAPTGS1ADORA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6150 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4628080-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRUG-RELATED PEPTIC ULCER COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-10-08 | — | — | EP | claimed |
| US-12364703-B2 | Homogeneous ophthalmic composition | ADCOX, JAMES M., III | 2025-07-22 | — | — | US | claimed |
| US-20250064760-A1 | INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | OCULAR THERAPEUTIX, INC. | 2025-02-27 | — | — | US | claimed |
| US-12226549-B2 | Synergistically cooperative compositions useful for soft tissue augmentation, drug delivery and related fields | ALTERGON S.A. (CH) | 2025-02-18 | — | — | US | claimed |
| EP-4470565-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-12-04 | — | — | EP | claimed |
| EP-4460285-A1 | INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | Ocular Therapeutix, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| CN-118742291-A | Intratubular insert comprising non-steroidal anti-inflammatory agent | 视尔普斯眼科公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118340907-A | Polymer conjugates comprising bioactive agents | 波利艾克蒂瓦有限公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2024117797-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRUG-RELATED PEPTIC ULCER COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 제일약품 주식회사 | 2024-06-06 | — | — | WO | claimed |
| EP-0569411-A1 | ACYLAMINO-ALKYLIDEN-HYDROXY-BISPHOSPHONIC ACIDS USEFUL IN THE THERAPY OF OSTEOARTICULAR DISEASES. | GENTILI IST SPA (IT) | 1993-11-18 | — | — | EP | claimed |
| EP-0537313-A1 | ARYLALKYL ESTERS OF 4,5-DIHYDROXY-9,10-DIHYDRO-9,10-DIOXO-2-ANTHRACENECARBOXYLIC ACID HAVING THERAPEUTICAL ACTIVITY. | GENTILI IST SPA (IT) | 1993-04-21 | — | — | EP | claimed |
| WO-1992019584-A1 | ARYLALKYL ESTERS OF 4,5-DIHYDROXY-9,10-DIHYDRO-9,10-DIOXO-2-ANTHRACENECARBOXYLIC ACID HAVING THERAPEUTICAL ACTIVITY | ISTITUTO GENTILI S.P.A. (IT) | 1992-11-12 | — | — | WO | claimed |
| WO-1992013864-A1 | ACYLAMINO-ALKYLIDEN-HYDROXY-BISPHOSPHONIC ACIDS USEFUL IN THE THERAPY OF OSTEOARTICULAR DISEASES | ISTITUTO GENTILI S.P.A. (IT) | 1992-08-20 | — | — | WO | claimed |
| EP-0466650-A2 | Improvements in non-steroidal anti-inflammatory therapy | WARNER-LAMBERT COMPANY (US) | 1992-01-15 | — | — | EP | claimed |
| EP-0221753-B1 | TRANSDERMAL TREATMENT FOR PAIN AND INFLAMMATION WITH 2-AMINO-3-AROYLBENZENEACETIC ACIDS, SALTS AND ESTERS | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-01-08 | — | — | EP | claimed |
| US-4683242-A | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-07-28 | — | — | US | claimed |
| EP-0221753-A2 | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-05-13 | — | — | EP | claimed |
| US-4221716-A | Intermediate and process for the preparation of 7-acylindolin-2-ones | A. H. ROBINS COMPANY, INC. (US) | 1980-09-09 | — | — | US | claimed |
| US-4045576-A | ANTI-INFLAMMATORY METHODS USING 2-AMINO-3-(5- AND 6-)BENZOYLPHENYLACETIC ACIDS, ESTERS AND METAL SALTS THEREOF AND THE COMPOUNDS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-08-30 | — | — | US | claimed |